Drug developer and diagnostics specialist ValiRx (LON:VAL) has appointed a chief commercial officer.
He is Samuel Ogunsalu, former head of commercialisation and the sector specialist for life sciences at the Knowledge East Partnership.
He was also a commercial development executive at Queen Mary Innovation, the technology company of Queen Mary College, London.
Ogunsalu has a background in microbiology and biochemical engineering and has 15 years' experience identifying and commercialising early and mid-stage innovations.
Chief executive Dr Satu Vainikka said: "I am delighted to be working with Sam again, this time under the ValiRx umbrella.
“And I look forward to benefitting from his past experience, contacts and intimate understanding of the challenges associated with the commercialisation and further development of companies and technologies in our space.
“ValiRx is now ready to change gear and Sam will help us to exploit value in our IP portfolio and prepare the Group for out-licensing partnerships and taking ValiRx to the next stage.”